Movatterモバイル変換


[0]ホーム

URL:


SG11201607070VA - Compositions and methods related to engineered fc constructs - Google Patents

Compositions and methods related to engineered fc constructs

Info

Publication number
SG11201607070VA
SG11201607070VASG11201607070VASG11201607070VASG11201607070VASG 11201607070V ASG11201607070V ASG 11201607070VASG 11201607070V ASG11201607070V ASG 11201607070VASG 11201607070V ASG11201607070V ASG 11201607070VASG 11201607070V ASG11201607070V ASG 11201607070VA
Authority
SG
Singapore
Prior art keywords
engineered
constructs
compositions
methods related
methods
Prior art date
Application number
SG11201607070VA
Inventor
Carlos J Bosques
James S Huston
Jonathan C Lansing
Leona E Ling
James Meador
Daniel Ortiz
Laura Rutitzky
Birgit C Schultes
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals IncfiledCriticalMomenta Pharmaceuticals Inc
Publication of SG11201607070VApublicationCriticalpatent/SG11201607070VA/en

Links

Classifications

Landscapes

SG11201607070VA2014-05-022015-05-01Compositions and methods related to engineered fc constructsSG11201607070VA (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US201461987863P2014-05-022014-05-02
US201462081923P2014-11-192014-11-19
PCT/US2015/028926WO2015168643A2 (en)2014-05-022015-05-01Compositions and methods related to engineered fc constructs

Publications (1)

Publication NumberPublication Date
SG11201607070VAtrue SG11201607070VA (en)2016-11-29

Family

ID=54359511

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG11201607070VASG11201607070VA (en)2014-05-022015-05-01Compositions and methods related to engineered fc constructs
SG10201913507SASG10201913507SA (en)2014-05-022015-05-01Compositions and methods related to engineered fc constructs

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
SG10201913507SASG10201913507SA (en)2014-05-022015-05-01Compositions and methods related to engineered fc constructs

Country Status (13)

CountryLink
US (4)US10239944B2 (en)
EP (2)EP3137506B1 (en)
JP (3)JP2017518965A (en)
KR (1)KR102546875B1 (en)
CN (2)CN106661125B (en)
AU (2)AU2015252866B2 (en)
CA (1)CA2941072A1 (en)
DK (1)DK3137506T5 (en)
ES (1)ES2962694T3 (en)
IL (3)IL286367B2 (en)
PL (1)PL3137506T3 (en)
SG (2)SG11201607070VA (en)
WO (1)WO2015168643A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JP6851200B2 (en)2014-03-052021-03-31ユーシービー バイオファルマ エスアールエル Multimeric Fc protein
CN106661125B (en)*2014-05-022021-10-01动量制药公司Compositions and methods relating to engineered Fc constructs
KR101997241B1 (en)2015-05-212019-07-09하푼 테라퓨틱스, 인크. Trispecific binding proteins and methods of use
ES2846024T7 (en)2015-07-242023-06-22Gliknik Inc Fusion Proteins of Human Protein Fragments to Create Orderly Multimerized Immunoglobulin Fc Compositions with Enhanced Complement Binding
ES2905536T3 (en)2015-10-022022-04-11Momenta Pharmaceuticals Inc Therapeutic and diagnostic procedures for autoimmune diseases and/or inflammation
ES2972740T3 (en)2016-03-022024-06-14Momenta Pharmaceuticals Inc Procedures related to genetically modified Fc constructs
AU2017268460B2 (en)2016-05-202023-12-14Harpoon Therapeutics, Inc.Single domain serum albumin binding protein
US11623958B2 (en)2016-05-202023-04-11Harpoon Therapeutics, Inc.Single chain variable fragment CD3 binding proteins
SG10202011624SA (en)*2016-05-232021-01-28Momenta Pharmaceuticals IncCompositions and methods related to engineered fc constructs
AU2017279538A1 (en)2016-06-072019-01-03Gliknik Inc.Cysteine-optimized stradomers
MY200137A (en)*2016-07-192023-12-08Ibentrus IncBispecific proteins and methods for preparing same
US20190389941A1 (en)2016-07-222019-12-26Gliknik Inc.Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
CN110022898B (en)*2016-12-092023-07-04格利克尼克股份有限公司Methods of treating inflammatory diseases with multivalent Fc compounds
PE20191354A1 (en)2016-12-092019-10-01Gliknik Inc MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER
CA3049383A1 (en)*2017-01-062018-07-12Momenta Pharmaceuticals, Inc.Compositions and methods related to engineered fc constructs
RU2019124709A (en)*2017-01-062021-02-08Момента Фармасьютикалз, Инк. COMPOSITIONS AND METHODS ASSOCIATED WITH DESIGNED CONSTRUCTIONS BASED ON Fc-ANTIGEN BINDING DOMAIN
US11535668B2 (en)*2017-02-282022-12-27Harpoon Therapeutics, Inc.Inducible monovalent antigen binding protein
JP7090347B2 (en)2017-05-122022-06-24ハープーン セラピューティクス,インク. Mesothelin-binding protein
PE20200495A1 (en)2017-06-022020-03-04Pfizer RECOMBINANT ROBO2 PROTEINS, COMPOSITIONS, METHODS AND USES OF THEM
AU2018302343B2 (en)*2017-07-212020-11-26Trianni, Inc.Single chain vh and heavy chain antibodies
US11077199B2 (en)2017-08-092021-08-03Massachusetts Institute Of TechnologyAlbumin binding peptide conjugates and methods thereof
IL315737A (en)2017-10-132024-11-01Harpoon Therapeutics IncB cell maturation antigen binding proteins
AU2017439776B2 (en)*2017-11-202025-03-27Taizhou Mabtech Pharmaceutical Co., LtdBifunctional fusion protein targeting CD47 and PD-l1
US20210147549A1 (en)*2018-07-112021-05-20Momenta Pharmaceuticals, Inc.COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1
KR20210042326A (en)*2018-07-112021-04-19모멘타 파머슈티컬스 인코포레이티드 Compositions and methods related to engineered Fc-antigen binding domain constructs
EP3820910A4 (en)*2018-07-112022-06-22Momenta Pharmaceuticals, Inc.Compositions and methods related to engineered fc-antigen binding domain constructs
BR112021000415A2 (en)*2018-07-112021-04-06Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO HANDLED FC-ANTIGEN CONNECTION CONSTRUCTIONS
US12195544B2 (en)2018-09-212025-01-14Harpoon Therapeutics, Inc.EGFR binding proteins and methods of use
CN113286817B (en)2018-09-252025-01-28哈普恩治疗公司 DLL3 binding proteins and methods of use
BR112021025426A2 (en)*2019-06-192022-06-21Bioverativ Therapeutics Inc Recombinant factor viii-fc for the treatment of hemophilia and low bone mineral density
KR20220062084A (en)2019-09-132022-05-13체에스엘 베링 렝나우 아게 Recombinant IgG Fc Multimers for the Treatment of Immune Complex-Mediated Renal Disorders
CN114786721A (en)2019-12-062022-07-22康诺贝林伦瑙有限公司Stabilized compositions of Fc multimers
IL318486A (en)2022-07-272025-03-01Ablynx NvPolypeptides binding to a specific epitope of the neonatal fc receptor
CN117986383A (en)*2022-11-022024-05-07北京昌平实验室 Fusion protein and its application
WO2024160721A1 (en)2023-01-302024-08-08Kymab LimitedAntibodies
TW202448926A (en)2023-02-172024-12-16比利時商艾伯霖克斯公司Polypeptides binding to the neonatal fc receptor

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
FR2556219B1 (en)1983-12-071987-06-26Merieux Inst NEW IMMUNOMODULATOR DRUG BASED ON HUMAN IGG FC FRAGMENTS
US5426641A (en)1994-01-281995-06-20Bell Communications Research, Inc.Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en)1995-03-011998-03-24Genentech, Inc.Method for making heteromultimeric polypeptides
AU3804397A (en)1996-06-141998-01-07Smithkline Beecham CorporationHexameric fusion proteins and uses therefor
US20090074839A1 (en)1997-01-222009-03-19Marton MilankovitsPharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US7951917B1 (en)1997-05-022011-05-31Genentech, Inc.Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en)*1997-05-022002-05-23Genentech, Inc.Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en)1999-01-152004-05-18Genentech, Inc.Polypeptide variants with altered effector function
EP2180054A1 (en)*1999-12-242010-04-28Genentech, Inc.Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050089932A1 (en)2001-04-262005-04-28Avidia Research InstituteNovel proteins with targeted binding
WO2005077981A2 (en)2003-12-222005-08-25Xencor, Inc.Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
US20060074225A1 (en)*2004-09-142006-04-06Xencor, Inc.Monomeric immunoglobulin Fc domains
JP5620626B2 (en)2005-03-312014-11-05中外製薬株式会社 Polypeptide production method by association control
US8354109B2 (en)*2005-12-132013-01-15Suppremol GmbhMultimeric Fc receptor polypeptides
GB0614780D0 (en)2006-07-252006-09-06Ucb SaBiological products
US7803769B2 (en)2006-10-252010-09-28Amgen Inc.OSK1 peptide analogs and pharmaceutical compositions
BRPI0620639A2 (en)2006-12-212011-11-22Micromet Ag bispecific single chain antibodies and pharmaceutical composition comprising the same
US20080260738A1 (en)2007-04-182008-10-23Moore Margaret DSingle chain fc, methods of making and methods of treatment
WO2008143954A2 (en)2007-05-142008-11-27Biogen Idec Ma Inc.Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP3409687A1 (en)2007-06-012018-12-05University of Maryland, BaltimoreImmunoglobulin constant region fc receptor binding agents
WO2010135521A2 (en)2009-05-202010-11-25Theraclone Sciences, Inc.Compositions and methods for the therapy and diagnosis of influenza
DK2235064T3 (en)*2008-01-072016-01-11Amgen IncA process for the preparation of heterodimeric Fc molecules using electrostatic control effects
ES2587937T3 (en)2008-04-022016-10-27Macrogenics, Inc. HER2 / neu specific antibodies and methods to use them
AU2009302582A1 (en)2008-10-062010-04-15University Of ChicagoCompositions and methods related to bacterial Eap, Emp, and/or AdsA proteins
US20100143353A1 (en)2008-12-042010-06-10Mosser David MPOLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME
WO2010080124A2 (en)2008-12-182010-07-15Dana-Farber Cancer Institute, Inc.Nkg2d-fc for immunotherapy
MX2011007833A (en)2009-01-232011-10-06Biogen Idec IncStabilized fc polypeptides with reduced effector function and methods of use.
EP2432451A2 (en)2009-05-202012-03-28Children's Medical Center CorporationCompositions for the treatment of metastatic cancer and methods of use thereof
AU2010273763B2 (en)2009-06-302013-11-21Research Development FoundationImmunoglobulin Fc polypeptides
AU2010296018B2 (en)2009-09-162016-05-05Genentech, Inc.Coiled coil and/or tether containing protein complexes and uses thereof
PT2486141T (en)2009-10-072018-05-09Macrogenics IncFc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
ES2688978T3 (en)2009-11-232018-11-07Amgen Inc. Fc monomeric antibody
GB0922209D0 (en)2009-12-182010-02-03Univ NottinghamProteins, nucleic acid molecules and compositions
BR112012029611A2 (en)2010-05-212017-07-25Merrimack Pharmaceuticals Inc bispecific fusion protein, pharmaceutical composition, method of treating tissue damage in an individual, method of promoting tissue regeneration or survival in an individual, and nucleic acid molecule
PT2591006T (en)2010-07-092019-07-29Bioverativ Therapeutics IncProcessable single chain molecules and polypeptides made using same
MX368531B (en)*2010-07-282019-10-07Gliknik IncFusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions.
EP2603526A1 (en)2010-08-132013-06-19Medimmune LimitedMonomeric polypeptides comprising variant fc regions and methods of use
PT2635607T (en)2010-11-052019-12-11Zymeworks IncStable heterodimeric antibody design with mutations in the fc domain
BR112013018317A2 (en)2010-12-232017-03-21Janssen Biotech Inc active protease resistant antibody fc mutants
WO2012123949A1 (en)2011-03-172012-09-20Ramot At Tel-Aviv University Ltd.Bi- and monospecific, asymmetric antibodies and methods of generating the same
SG188638A1 (en)2011-03-252013-05-31Glenmark Pharmaceuticals SaHetero-dimeric immunoglobulins
EP2807194A4 (en)*2012-01-272015-12-02Gliknik Inc FUSION PROTEINS COMPRISING IGG2 HINGED DOMAINS
JP2015521589A (en)2012-06-082015-07-30バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. Procoagulant compounds
WO2013192131A1 (en)2012-06-212013-12-27Indiana University Research And Technology CorporationIncretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
BR112015003459A2 (en)*2012-08-202017-09-26Gliknik Inc molecules with polyvalent fc gamma antigen binding and receptor binding activity
CN104870055A (en)2012-10-172015-08-26利物浦热带医学院Immunomodulatory proteins
CN104558194B (en)2013-10-172018-04-27泰州迈博太科药业有限公司A kind of anti-CD20-Flex bifunctional fusion proteins, preparation method and the usage
CA2930307A1 (en)2013-11-132015-05-21Zymeworks Inc.Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
JP2017504598A (en)2013-12-202017-02-09インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Lipidated incretin receptor ligand human immunoglobulin FC-region fusion polypeptide
WO2015107025A1 (en)2014-01-152015-07-23F. Hoffmann-La Roche AgFc-region variants with modified fcrn-binding properties
RU2727639C2 (en)2014-01-152020-07-22Ф.Хоффманн-Ля Рош АгVariants of fc-region with modified ability to bind to fcrn and with preserved ability to bind with protein a
JP6851200B2 (en)2014-03-052021-03-31ユーシービー バイオファルマ エスアールエル Multimeric Fc protein
EP3114137A1 (en)2014-03-052017-01-11UCB Biopharma SPRLMultimeric fc proteins
JP2017513481A (en)2014-04-162017-06-01ユーシービー バイオファルマ エスピーアールエル Multimeric Fc protein
CN106661125B (en)*2014-05-022021-10-01动量制药公司Compositions and methods relating to engineered Fc constructs
CN113549153A (en)2014-05-292021-10-26宏观基因有限公司Trispecific binding molecules and methods of use thereof
ES2972740T3 (en)2016-03-022024-06-14Momenta Pharmaceuticals Inc Procedures related to genetically modified Fc constructs
SG10202011624SA (en)2016-05-232021-01-28Momenta Pharmaceuticals IncCompositions and methods related to engineered fc constructs
CA3049383A1 (en)2017-01-062018-07-12Momenta Pharmaceuticals, Inc.Compositions and methods related to engineered fc constructs

Also Published As

Publication numberPublication date
IL274735A (en)2020-07-30
NZ724375A (en)2024-07-05
US20190225688A1 (en)2019-07-25
AU2015252866A1 (en)2016-09-15
JP7600172B2 (en)2024-12-16
JP2020128415A (en)2020-08-27
AU2015252866B2 (en)2021-01-28
AU2021202578A1 (en)2021-05-27
SG10201913507SA (en)2020-02-27
CN106661125B (en)2021-10-01
ES2962694T3 (en)2024-03-20
JP2017518965A (en)2017-07-13
IL247442B (en)2021-02-28
DK3137506T5 (en)2024-10-14
IL274735B (en)2021-10-31
US12071482B2 (en)2024-08-27
US20170066826A2 (en)2017-03-09
CN113501880A (en)2021-10-15
WO2015168643A2 (en)2015-11-05
CA2941072A1 (en)2015-11-05
JP7593745B2 (en)2024-12-03
BR112016024780A2 (en)2017-10-10
WO2015168643A3 (en)2015-12-23
US10239944B2 (en)2019-03-26
IL286367B (en)2022-11-01
US20250011432A1 (en)2025-01-09
EP3137506A2 (en)2017-03-08
CN106661125A (en)2017-05-10
IL247442A0 (en)2016-11-30
US20160229913A1 (en)2016-08-11
AU2021202578B2 (en)2024-09-26
EP3137506A4 (en)2017-12-06
KR102546875B1 (en)2023-06-26
EP4299595A3 (en)2024-03-13
US20220033499A1 (en)2022-02-03
JP2022095892A (en)2022-06-28
KR20160147762A (en)2016-12-23
PL3137506T3 (en)2024-02-26
IL286367A (en)2021-10-31
US11124573B2 (en)2021-09-21
EP4299595A2 (en)2024-01-03
EP3137506B1 (en)2023-08-30
DK3137506T3 (en)2023-10-02
IL286367B2 (en)2023-03-01

Similar Documents

PublicationPublication DateTitle
IL286367A (en)Compositions and methods related to engineered fc constructs
IL263211B1 (en)Compositions and methods related to engineered fc constructs
HK1247238B (en)Engineered crispr-cas9 compositions and methods of use
GB2535253B (en)Compositions and methods
IL250568A0 (en)Anti-methanogenic compositions and uses thereof
ZA201702794B (en)Cellulose-containing compositions and methods of making same
HUE056172T2 (en)Compositions of selenoorganic compounds and methods of use thereof
ZA201701909B (en)Trichoderma compositions and methods of use
GB201417828D0 (en)New methods and compositions
IL246879A0 (en)Apilimod compositions and methods for using same
SG11201607736UA (en)Engineered chimeric pegylated adi and methods of use
SG10202107391YA (en)Compositions and methods related to engineered fc constructs
IL234929A0 (en)Liposomes-containing antifouling compositions and uses thereof
PL3113774T3 (en)Compositions of grapiprant and methods for using the same
HK1243404A1 (en)Tryptamide compositions and methods of use
GB201421430D0 (en)Antibodies to Adam17 and uses thereof
GB201402915D0 (en)Compositions and methods
GB201403212D0 (en)Compositions and methods

[8]ページ先頭

©2009-2025 Movatter.jp